Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01223235 · ClinicalTrials.gov registry record · NA
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT01223235: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01223235 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01223235, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells. The purpose of this study is to test whether it is safe to treat the cancer with a vaccine and another drug called bevacizumab (also known as Avastin).
Primary Outcome
Toxicities evaluated by CTCAE version 4.0
Interventions
- BIOLOGICAL bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-10 |
| Est. Completion | 2017-09 |
| Phase | NA |
What the finished NCT01223235 record still lists
NCT01223235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 is the first listed.
NCT01223235 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01223235 about?
NCT01223235 is a clinical study titled "Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab". The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells. The purpose of this study is to test whether it is safe to treat the cancer with a vaccine and anot...
What is the current status of trial NCT01223235?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2010-10. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01223235?
The interventions under investigation include: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01223235?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01223235's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia